Pertussis and Rotavirus Vaccines – Controversies and Solutions

Review Article

Abstract

Pertussis and rotavirus vaccines have been the subject of several controversies over the years. In this paper the authors discuss facts and myths behind these controversies and also suggest solutions to overcome some limitations of these vaccines. The whole-cell pertussis vaccine (wPV) came into disrepute due to the associated adverse reactions, resulting in its replacement by acellular pertussis vaccine (aPV) in industrialized nations in 1990s. Although wPV is known to have more side effects; but they are usually minor. Whole-cell pertussis containing vaccine is being used safely in the National Immunization programme in India from many years. Another controversy erupted during 2009–2010, when there were reports of resurgence of pertussis cases among adolescents and adults, from developed nations. Present literature review raises doubts about long term protection offered by aPV, when compared with wPV. In spite of prevailing controversy, acellular pertussis containing vaccines should be acceptable, if timely delivery of primary and booster doses is ensured; including vaccination of adolescents and pregnant women. Initial rotavirus vaccine was withdrawn from the market because of increased risk of intussusception. Although three new generation rotavirus vaccines are currently available for use in India, but doubts about their efficacy, long term protection and safety still exists. Present literature review found them to be safe and moderately efficacious because of reasonable good cross protection. Even a moderately efficacious vaccine like rotavirus vaccine could significantly improve the outcome if disease burden is high. Therefore, it is being included in National Immunization Programme of India.

Keywords

Whooping cough Gastroenteritis Immunization Health policy 

References

  1. 1.
    Pertussis vaccines. WHO position paper. Wkly Epidemiol Rec. 2015;90:433–60.Google Scholar
  2. 2.
    Pertussis vaccines. WHO position paper. Vaccine. 2016;34:1423–5.Google Scholar
  3. 3.
    Pertussis. WHO Programmes. Vaccines and Biologicals, Global figures. 2015. Available at: http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis/en/. Accessed 22 Mar 2017.
  4. 4.
    WHO vaccine reaction rates information sheets. Available at: http://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/. Accessed 22 Mar 2017.
  5. 5.
    Joyce R. Monovalent pertussis vaccine no longer available. BMJ. 1994;308:343.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. China: Elsevier Saunders; 2013. p. 447–92.CrossRefGoogle Scholar
  7. 7.
    Kulenkampff M, Schwartzman JS, Wilson J. Neurological complications of pertussis inoculation. Arch Dis Child. 1974;49:46–9.Google Scholar
  8. 8.
    Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movement on pertussis control: the untold story. Lancet. 1998;351:356–61.Google Scholar
  9. 9.
    Coulter HL, Fisher BL. A shot in the dark: why the P in the DTP vaccination may be hazardous to your child's health. New York: Avery Publishing Group Inc; 1991.Google Scholar
  10. 10.
    Baraff LJ, Ablon WJ, Weiss RC. Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr Infect Dis. 1983;2:7–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Alderslade R, Bellman MH, Rawson NSB, Ross EM, Miller DL. The National Childhood Encephalopathy study: a report of 1000 cases of serious neurological disorders in infants and young children from the NCES research team. Department of Health and Social Security. Whooping cough: reports from the committee on the safety of medicines and the joint committee on vaccination and immunization. London: Her Majesty’s Stationery Office; 1981.Google Scholar
  12. 12.
    Stephenson JB. A neurologist looks at neurological disease temporally related to DTP immunization. Tokai J Exp Clin Med. 1988;13:S157–64.Google Scholar
  13. 13.
    Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J. 2006;25:768–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Blumberg DA, Lewis K, Mink CM, Christenson PD, Chatfield P, Cherry JD. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics. 1993;91:1158–65.PubMedGoogle Scholar
  15. 15.
    Institute of Medicine (US). Committee to study new research on vaccines. In: Stratton KR, Howe CJ, Johnston RB, editors. DPT vaccine and chronic nervous system dysfunction: a new analysis. Washington (DC): National Academy Press; 1994.Google Scholar
  16. 16.
    Institute of Medicine (US). Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. In: Howson CP, Howe CJ, Fineberg HV, editors. Adverse effects of pertussis and Rubella vaccines: a report of the committee to review the adverse consequences of pertussis and Rubella vaccines. Washington (DC): National Academy Press; 1991.Google Scholar
  17. 17.
    Baraff LJ, Ablon WJ, Weiss RC. Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr Infect Dis. 1983;2:7–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Bernier RH, Frank JA Jr, Dondero TJ Jr, Turner P. Diphtheria-tetanus toxoid-pertussis vaccination and sudden infant deaths in Tennessee. J Pediatr. 1982;101:419–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Torch WS. Diphtheria-pertussis-tetanus (DPT) immunization: a potential cause of the Sudden Infant Death Syndrome (SIDS). Neurology. 1982;32:A169. abstractCrossRefGoogle Scholar
  20. 20.
    Griffin MR, Ray WA, Livengood JR, Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med. 1988;319:618–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Hoffman HJ, Hunter JC, Damus K, et al. Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. Pediatrics. 1987;79:598–611.Google Scholar
  22. 22.
    Valdes-Dapena M. Sudden infant death syndrome: overview of recent research developments from a pediatric pathologist's perspective. Paediatrician. 1988;15:222–30.Google Scholar
  23. 23.
    Heininger U, Kleemann WJ, Cherry JD; Sudden Infant Death Syndrome Study Group. A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics. 2004;114:e9–15.Google Scholar
  24. 24.
    Cherry JD. The history of pertussis (whooping cough); 1906–2015: facts, myths, and misconceptions. Curr Epidemiol Rep. 2015;2:120–30.CrossRefGoogle Scholar
  25. 25.
    Geier DA, Geier MR. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines. Brain Dev. 2004;26:296–300.Google Scholar
  26. 26.
    WHO SAGE pertussis working group Background paper. SAGE April 2014. Available at: http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf. Accessed 22 Mar 2017.
  27. 27.
    Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308:454–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308:2126–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a north American outbreak. Clin Infect Dis. 2012;54:1730–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis. 2014;209:978–81.CrossRefPubMedGoogle Scholar
  31. 31.
    Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111:787–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med. 2015;13:146.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lapidot R, Gill CJ. The pertussis resurgence: putting together the pieces of the puzzle. Trop Dis Travel Med Vac. 2016;2:26.CrossRefGoogle Scholar
  34. 34.
    Ausiello CM, Cassone A. Acellular pertussis vaccines and pertussis resurgence: revise or replace. MBio. 2014;5:e01339–14.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Thorstensson R, Trollfors B, Al-Tawii N, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014;9:e83449.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Vashishtha VM, Bansal CP, Gupta SG. Pertussis vaccines: position paper of Indian Academy of Pediatrics (IAP). Indian Pediatr. 2013;50:1001–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Rotavirus vaccine. WHO position paper. Wkly Epidemiol Rec. 2013;88:49–64.Google Scholar
  38. 38.
    Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. India rotavirus vaccine group. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomized, double-blind, placebo-controlled trial. Lancet. 2014;383:2136–43.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Verma S. IAP immunization timetable 2012 clarifications. Indian Pediatr. 2012;49:997–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–98.CrossRefPubMedGoogle Scholar
  41. 41.
    John TJ. Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial? Indian Pediatr. 2015;52:906.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang W, Azevedo MS, Wen K, et al. Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs. Vaccine. 2008;26:3655–61.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310–2.CrossRefPubMedGoogle Scholar
  44. 44.
    Tissera MS, Cowley D, Bogdanovic-Sakran N, et al. Options for improving effectiveness of rotavirus vaccines in developing countries. Hum Vaccin Immunother. 2016 Nov 11:1–7. doi:10.1080/21645515.2016.1252493.
  45. 45.
    Esona MD, Mijatovic-Rustempasic S, Yen C, et al. Detection of PCV-2 DNA in stool samples from infants vaccinated with RotaTeq. Hum Vaccin Immunother. 2014;10:25–32.CrossRefPubMedGoogle Scholar
  46. 46.
    Bines JE, Danchin M, Jackson P, Handley A, et al. RV3 Rotavirus Vaccine Program. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15:1389–97.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  1. 1.Department of Pediatrics, Advanced Pediatric Centre (APC)Postgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations